Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: A clinical series

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 6, 2011, Pages 294-298

  Cordero Ruiz, Patricia ^a   Castro Márquez, Cristina ^a   Méndez Rufián, Vanesa ^a   Castro Laria, Luisa ^a   Caunedo Álvarez, Ángel ^a   Romero Vázquez, Javier ^a   Herrerías Gutiérrez, Juan Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Adalimumab; Crohn's disease; Infliximab; Intolerance; Loss of response

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; COLON FISTULA; CROHN DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE PAIN; MALE; PROTEIN BLOOD LEVEL; REMISSION; SMALL INTESTINE OBSTRUCTION; TUBERCULOUS MENINGITIS;

EID: 80054680220     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011000600003     Document Type: Article

References (16)

1. Rutgeerts P, Van Assche G, Vermiere S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126: 1593-610.
2. Mease PJ. Adalimumab in the treatment of arthritis. Ther Clin Risk Manag 2007;3(1):133-48.
3. Peyrin-biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007;25:675-80.
4. Seiderer J, Brand S, Dambacher J, Pfenning S, Jürgens M, Göke B, et al. Adalimumab in patients with Crohn s disease -safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25:787-96.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, McIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn s disease: the CLASSIC-I trial. Gas-troenterology 2006;130:323-33.
6. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn s disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
7. Allez M, Vermiere S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. Efficacy and safety o a third anti-TNF monoclonal antibody in Crohn s disease after failure of two other anti-TNF. Aliment Pharmacol Ther 2009;26.
8. López Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Díaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn s disease. An open-label study. Rev Esp Enferm Dig 2008; 100:676-81.
9. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanuer SB, Panac-cione R, et al. Adalimumab form maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65.
10. Barreiro-de Acosta M, Ouburg S, Morré SA, Crusius JB, Lorenzo A, Potel J, et al. NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn s disease: a preliminary report. Rev Esp Enferm Dig 2010;102:591-5.
11. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpa-trick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
12. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastro-enterol Hepatol 2009;24:1252-7.
13. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Pa-naccione R, et al. Adalimumab induction therapy for crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007;146:829-38.
14. Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J, et al. The use of adalimumab in the management of refractory Crohn s disease. Aliment Pharmacol Ther 2007;27:308-15.
15. Sandborn WJ, Hanauer S, Loftus Ev Jr, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn s disease. Am J Gastroenterol 2004; 99:1984-9.
16. Hinojosa J, Gomollón F, Garcia S, Bastida G, Cabriada JL, Saro C, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007;25:409-18.